Dynavax Technologies Corporation (DVAX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Dynavax Technologies Corporation (DVAX) Bundle
Discover the true value of Dynavax Technologies Corporation (DVAX) with our professional-grade DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes affect the valuation of Dynavax Technologies Corporation (DVAX) – all within one convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.2 | 46.6 | 439.4 | 722.7 | 232.3 | 307.1 | 405.9 | 536.6 | 709.3 | 937.7 |
| Revenue Growth, % | 0 | 32.18 | 844 | 64.45 | -67.86 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 |
| EBITDA | -114.1 | -46.8 | 95.7 | 307.7 | 9.7 | -80.7 | -106.7 | -141.1 | -186.5 | -246.6 |
| EBITDA, % | -323.95 | -100.63 | 21.78 | 42.58 | 4.16 | -26.3 | -26.3 | -26.3 | -26.3 | -26.3 |
| Depreciation | 21.5 | 9.3 | 7.0 | 6.7 | 7.3 | 53.3 | 70.5 | 93.2 | 123.2 | 162.9 |
| Depreciation, % | 61.13 | 20.05 | 1.6 | 0.92267 | 3.13 | 17.37 | 17.37 | 17.37 | 17.37 | 17.37 |
| EBIT | -135.6 | -56.2 | 88.7 | 301.0 | 2.4 | -84.2 | -111.3 | -147.2 | -194.5 | -257.2 |
| EBIT, % | -385.08 | -120.68 | 20.18 | 41.65 | 1.03 | -27.43 | -27.43 | -27.43 | -27.43 | -27.43 |
| Total Cash | 151.1 | 165.0 | 546.0 | 624.4 | 742.3 | 298.7 | 394.9 | 522.0 | 690.0 | 912.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 8.9 | 22.7 | 131.8 | 147.5 | 44.5 | 88.1 | 116.5 | 154.0 | 203.6 | 269.1 |
| Account Receivables, % | 25.23 | 48.68 | 30 | 20.41 | 19.17 | 28.7 | 28.7 | 28.7 | 28.7 | 28.7 |
| Inventories | 41.3 | 63.7 | 61.3 | 59.4 | 53.3 | 150.5 | 199.0 | 263.1 | 347.8 | 459.7 |
| Inventories, % | 117.36 | 136.82 | 13.96 | 8.23 | 22.94 | 49.02 | 49.02 | 49.02 | 49.02 | 49.02 |
| Accounts Payable | 9.3 | 3.3 | 2.6 | 3.2 | 5.2 | 22.6 | 29.8 | 39.4 | 52.1 | 68.9 |
| Accounts Payable, % | 26.34 | 7.11 | 0.59166 | 0.44432 | 2.26 | 7.35 | 7.35 | 7.35 | 7.35 | 7.35 |
| Capital Expenditure | -29.4 | -11.1 | -9.5 | -7.1 | -4.1 | -68.9 | -91.1 | -120.4 | -159.1 | -210.4 |
| Capital Expenditure, % | -83.48 | -23.78 | -2.16 | -0.98785 | -1.77 | -22.44 | -22.44 | -22.44 | -22.44 | -22.44 |
| Tax Rate, % | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 | -46.3 |
| EBITAT | -134.6 | -68.5 | 87.8 | 299.9 | 3.5 | -83.8 | -110.8 | -146.5 | -193.7 | -256.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -183.4 | -112.4 | -22.2 | 286.2 | 117.8 | -222.9 | -201.0 | -265.7 | -351.2 | -464.3 |
| WACC, % | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 | 9.94 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,098.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -474 | |||||||||
| Terminal Value | -5,965 | |||||||||
| Present Terminal Value | -3,714 | |||||||||
| Enterprise Value | -4,813 | |||||||||
| Net Debt | 107 | |||||||||
| Equity Value | -4,919 | |||||||||
| Diluted Shares Outstanding, MM | 129 | |||||||||
| Equity Value Per Share | -38.21 |
What You Will Get
- Real Dynavax Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Dynavax's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to reliable historical data and future forecasts for Dynavax Technologies Corporation (DVAX).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: Utilize intuitive charts and summaries to clearly visualize your valuation outcomes.
- Suitable for All Experience Levels: Designed with an easy-to-navigate format for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-formatted Excel file containing Dynavax Technologies Corporation’s (DVAX) financial information.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and evaluate results side by side effortlessly.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for Dynavax Technologies Corporation (DVAX)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, investment managers, and industry consultants.
- Accurate Data: Dynavax’s historical and projected financial information is preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them to real-world scenarios.
- Researchers: Utilize advanced models for analyzing vaccine efficacy and safety data.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Dynavax Technologies Corporation (DVAX).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Professionals: Understand how biotech companies like Dynavax are assessed in the market.
What the Template Contains
- Pre-Filled DCF Model: Dynavax Technologies Corporation’s (DVAX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to Dynavax.
- Financial Ratios: Evaluate Dynavax’s profitability, leverage, and efficiency metrics.
- Editable Inputs: Adjust assumptions such as growth rates, margins, and CAPEX to tailor your analysis.
- Financial Statements: Comprehensive annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and outcomes for Dynavax.